John joined Sofinnova BioEquities as an Analyst in 2024. He focuses on public biotech investments in all therapeutic areas.
Prior to joining Sofinnova, John began his investing career as a biotech Analyst at Parkman Healthcare Partners covering all SMid cap therapeutic areas. Before public investing, John joined the Street at Leerink covering SMid cap oncology.
John earned a Ph.D. in Molecular Engineering from the University of Chicago and a B.S. in Biomedical Engineering from Boston University.